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ABSTRACT
OBJECTIVE
To determine whether coronary computed tomography 
angiography (CTA) should be performed in patients 
with any clinical probability of coronary artery disease 
(CAD), and whether the diagnostic performance differs 
between subgroups of patients.
DESIGN
Prospectively designed meta-analysis of individual 
patient data from prospective diagnostic accuracy 
studies.
DATA SOURCES
Medline, Embase, and Web of Science for published 
studies. Unpublished studies were identified via 
direct contact with participating investigators.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Prospective diagnostic accuracy studies that 
compared coronary CTA with coronary angiography 
as the reference standard, using at least a 50% 
diameter reduction as a cutoff value for obstructive 
CAD. All patients needed to have a clinical indication 
for coronary angiography due to suspected CAD, and 
both tests had to be performed in all patients. Results 
had to be provided using 2×2 or 3×2 cross tabulations 
for the comparison of CTA with coronary angiography. 
Primary outcomes were the positive and negative 
predictive values of CTA as a function of clinical 
pretest probability of obstructive CAD, analysed by 
a generalised linear mixed model; calculations were 
performed including and excluding non-diagnostic 
CTA results. The no-treat/treat threshold model was 
used to determine the range of appropriate pretest 
probabilities for CTA. The threshold model was based 
on obtained post-test probabilities of less than 15% 
in case of negative CTA and above 50% in case of 
positive CTA. Sex, angina pectoris type, age, and 
number of computed tomography detector rows were 
used as clinical variables to analyse the diagnostic 
performance in relevant subgroups.
RESULTS
Individual patient data from 5332 patients from 
65 prospective diagnostic accuracy studies were 
retrieved. For a pretest probability range of 7-67%, 
the treat threshold of more than 50% and the no-treat 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Coronary computed tomography angiography (CTA) is an accurate non-invasive 
alternative to invasive coronary angiography, and can rule out coronary artery 
disease (CAD) with high certainty
By contrast with recent guidelines from the National Institute for Health and Care 
Excellence, the European Society of Cardiology recommends not considering 
CTA in all patients with typical and atypical angina, but only in patients with a 
15-50% pretest probability of CAD, estimated by clinical information such as sex, 
age, and chest pain type
WHAT THIS STUDY ADDS
According to a no-treat/treat threshold model, patients with a pretest probability 
of CAD ranging from 7% to 67% could benefit most from coronary CTA to rule out 
or confirm CAD
CTA using more than 64 detector rows was empirically more sensitive and 
specific than CTA using up to 64 detector rows
Performance of CTA was not influenced by the angina pectoris type and was 
slightly higher in men and lower in older patients
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threshold of less than 15% post-test probability were 
obtained using CTA. At a pretest probability of 7%, 
the positive predictive value of CTA was 50.9% (95% 
confidence interval 43.3% to 57.7%) and the negative 
predictive value of CTA was 97.8% (96.4% to 98.7%); 
corresponding values at a pretest probability of 67% 
were 82.7% (78.3% to 86.2%) and 85.0% (80.2% to 
88.9%), respectively. The overall sensitivity of CTA was 
95.2% (92.6% to 96.9%) and the specificity was 79.2% 
(74.9% to 82.9%). CTA using more than 64 detector rows 
was associated with a higher empirical sensitivity than 
CTA using up to 64 rows (93.4% v 86.5%, P=0.002) and 
specificity (84.4% v 72.6%, P<0.001). The area under the 
receiver-operating-characteristic curve for CTA was 0.897 
(0.889 to 0.906), and the diagnostic performance of 
CTA was slightly lower in women than in with men (area 
under the curve 0.874 (0.858 to 0.890) v 0.907 (0.897 to 
0.916), P<0.001). The diagnostic performance of CTA was 
slightly lower in patients older than 75 (0.864 (0.834 
to 0.894), P=0.018 v all other age groups) and was not 
significantly influenced by angina pectoris type (typical 
angina 0.895 (0.873 to 0.917), atypical angina 0.898 
(0.884 to 0.913), non-anginal chest pain 0.884 (0.870 to 
0.899), other chest discomfort 0.915 (0.897 to 0.934)).
CONCLUSIONS
In a no-treat/treat threshold model, the diagnosis 
of obstructive CAD using coronary CTA in patients 
with stable chest pain was most accurate when the 
clinical pretest probability was between 7% and 67%. 
Performance of CTA was not influenced by the angina 
pectoris type and was slightly higher in men and lower 
in older patients.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42012002780.
Introduction
It is currently unclear in which subgroups of patients 
with suspected coronary artery disease (CAD) computed 
tomography angiography (CTA) has highest diagnostic 
clinical performance. Current guidelines recommend 
choosing the type of first line imaging test by taking 
the pretest probability of CAD into account, because it 
substantially affects diagnostic accuracy.1-3 According 
to the most recent recommendation of the National 
Institute for Health and Care Excellence,4 coronary 
CTA should be the primary imaging test in patients 
with suspected CAD and possible angina, while the 
guidelines of the European Society of Cardiology on 
the management of CAD recommend considering 
CTA only in patients with a CAD pretest probability 
of 15-50%.3 4 Moreover, little is known about CTA’s 
diagnostic performance in clinically important patient 
subgroups such as sex, age, and angina pectoris type 
and its association with the estimated clinical pretest 
probability of CAD.
Optimising the use of diagnostic imaging tests in 
patients with suspected CAD is crucial, given that about 
two thirds of invasive coronary angiograms performed 
in Europe and the United States show no evidence 
of obstructive CAD and increasing use of cardiac 
imaging tests poses a burden on healthcare costs.5 6 
CTA has the potential to reliably exclude obstructive 
CAD,7 8 while halving the events of coronary heart 
disease after five years of follow-up9 and improving 
the diagnostic yield of coronary angiography.8 10 Its 
implementation as a first line diagnostic imaging test 
in patients with suspected CAD remains controversial. 
Since available diagnostic accuracy studies of CTA 
are moderate in size, data pooling can provide a more 
accurate assessment of its diagnostic performance. 
Individual patient data allow researchers to evaluate 
clinically important subgroups and individually 
estimate the pretest probability and to determine its 
effect on the diagnostic test performance of CTA. With 
the rationale to define the clinical context and clinical 
probability in which CTA has highest discriminative 
ability to diagnose or rule out CAD, we formed the 
COME-CCT (Collaborative Meta-Analysis of Cardiac 
CT) Consortium to pool patient level data from 
diagnostic accuracy studies of CTA enrolling patients 
with a clinical indication for coronary angiography as 
the reference standard for angiographic CAD.11 This 
work will help clinicians identify those patients with 
stable chest pain for whom CTA is most suitable.
Methods
Study design and main objectives
COME-CCT is a collaborative meta-analysis using 
individual patient data (IPD) to summarise the 
published and unpublished evidence on the diagnostic 
performance of cardiac CTA, and the protocol has been 
published.11 The main objective was to assess the 
influence of the clinical pretest probability of CAD on 
the diagnostic accuracy of cardiac CTA in order to define 
CTA’s clinical discriminative ability for diagnosing or 
ruling out CAD depending on clinical risk. Therefore, 
we used a no-treat/treat threshold approach to define 
the pretest probability range for which CTA has highest 
diagnostic value and, vice versa, for which CTA is not 
appropriate, to better decide which patients to offer the 
test to.12 Positive and negative predictive values (PPVs 
and NPVs) were chosen as primary outcome measures 
as a function of pretest probability.13 Finally, the 
influence of sex, age, angina pectoris type, and number 
of CT detector rows on the diagnostic performance of 
coronary CTA was analysed in this primary outcomes 
publication. We used the PRISMA (preferred reporting 
items for systematic reviews and meta-analyses) 
statement for IPD systematic reviews for reporting this 
collaborative meta-analysis (checklist in web appendix 
1).14 COME-CCT was designed in a multicentric and 
multicontinental fashion according to a prespecified 
study protocol,11 and the COME-CCT IPD meta-analysis 
was registered at PROSPERO.
Eligibility criteria and study selection
COME-CCT was designed as a prospective meta-
analysis of IPD from prospective diagnostic accuracy 
studies comparing coronary CTA with invasive coronary 
angiography as the reference standard. Both tests used 
a diameter stenosis of at least 50% as the cutoff value 
to define angiographically obstructive CAD.
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Eligible patients needed to have a clinical indication 
for coronary angiography due to suspected CAD 
because of stable chest pain, and both tests had to be 
performed in all patients to avoid verification bias.15 
Results had to be provided using 2×2 or 3×2 cross 
tabulations for the comparison of CTA with coronary 
angiography.16 For the calculation of clinical pretest 
probability using an updated version of the Diamond 
and Forrester method,17 18 the following information 
had to be provided: patient age, sex, and angina pectoris 
type.19  20 Angina pectoris was classified as typical 
angina, atypical angina, non-anginal chest pain, or 
other chest discomfort according to Diamond and 
Forrester. The primary analysis included all patients 
irrespective of whether they had diagnostic or non-
diagnostic (that is, unevaluable) CTA examinations.16
The search was performed in three databases (Medline, 
Embase, and Web of Science; sensitive search strategy 
described in web appendix 2).21 The search strategy was 
implemented for every database by two independent 
investigators of the central data management team, as 
described in the published protocol.11
Collection and harmonisation of individual patient 
level data
When the search was completed, we started IPD 
collection and subsequent data harmonisation. As 
defined in the study protocol,11 we emailed corres-
ponding authors of eligible published studies identi-
fied by the search with a cover letter detailing the 
objectives of the collaborative meta-analysis and a CD 
containing a uniform IPD collection file (web appendix 
3).11 Other authors were contacted if the corresponding 
author did not respond. Data from unpublished 
studies that met the inclusion criteria were retrieved 
from corresponding authors of published studies.22 
The completed IPD collection files were sent back to 
the data management team.
Data harmonisation was performed by two 
independent readers at the site of the central data 
management team, who analysed data and searched 
for non-plausible data, including range checks, average 
and median checks (v published aggregated data 
results), minimum and maximum checks (v aggregated 
data results), wrong entries, non-logical values, and 
other data checks. Aggregate data of studies for which 
IPD were not provided were collected and compared 
with aggregate data of studies for which IPD were 
provided to rule out study selection bias. Aggregate 
data consisted of all data necessary for 2×2 tabulations 
to estimate sensitivity, specificity, and PPVs and NPVs, 
and to perform receiver operating characteristic curves 
analysis. Risk of bias and applicability concerns of the 
included studies were assessed by two independent 
readers of the central data management team, who 
were not involved in data harmonisation, using the 
QUADAS-2 tool.23
Primary and secondary outcomes
The primary outcomes of interest were the PPV and 
NPV of coronary CTA for the presence of obstructive 
CAD as measures of the post-test probability of disease 
needed for the no-treat/treat threshold model. PPV 
and NPV were evaluated as a function of the pretest 
probability of obstructive CAD and analysed by a 
generalised linear mixed model meta-regression 
including non-diagnostic CTA results.11 To define 
the range of appropriate pretest probabilities of 
obstructive CAD for CTA, we used the no-treat/treat 
threshold method.12 Following the European Society 
of Cardiology guidelines, the no-treat/treat thresholds 
for CTA were 15% and 50%, respectively, on the 
disease probability range. This means that for disease 
probabilities below 15%, other reasons for the chest 
pain should be considered, and for values above 50%, 
ischaemia testing should be recommended.3
Secondary outcomes were sensitivity and specificity 
analyses in women and men, in patients of different 
age groups, and with different angina pectoris types. 
Diagnostic performance of CTA was descriptively 
compared in computed tomography scanners with 
up to 64 detector rows versus those with more than 
64 detector rows. A further post hoc analysis, which 
was not defined in the protocol of COME-CCT, were 
requested by reviewers: we analysed the use of core 
laboratories and quantitative coronary angiography in 
relation to diagnostic accuracy of CTA.
Statistical analysis
Using an intention-to-diagnose approach, we imple-
mented a worst case scenario in which non-diagnostic 
CTA results were considered false positive if coronary 
angiography was negative, and considered false 
negative if coronary angiography was positive.16 
We calculated clinical pretest probability using the 
validated CAD Consortium prediction tool, which 
is an updated version of the Diamond and Forrester 
model.17  18 Specifically, probability was estimated 
using all elements of the prediction tool: patient 
age, sex, and clinical presentation (angina pectoris 
type). Based on this model, mean logit PPVs and 
NPVs with their standard errors and 95% confidence 
intervals were estimated. These quantities were back-
transformed to the original scale to obtain summary 
PPVs and NPVs. For the statistical analysis, we applied 
a univariate logistic regression model24 extended by 
incorporating a random effect for study and a random 
slope for CTA or coronary angiography results, which 
is equivalent to a bivariate generalised linear mixed 
model.25 To maintain equivalence, interaction terms of 
CTA and covariates of interest are necessary and were 
thus included into the model. Using these data and 
model, we performed a statistical prediction for a new 
cohort following the ideas presented by Skrondal and 
Rabe-Hasketh.26 27
To apply the no-treat/treat CAD probability thres-
holds for CTA, we chose two post-test probabilities 
to define the range when to offer CTA: below 15% 
when other reasons for the chest pain should then be 
considered (no treat threshold) and probabilities above 
50% when ischaemia testing is then recommended 
(treat threshold). We then calculated the clinical 
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prediction score pretest probabilities that yielded post-
test probabilities after negative CTA of below 15% 
(that is, a NPV of at least 85%) and those after positive 
CTA of above 50% (that is, a PPV of at least 50%). In 
addition to the model in which non-diagnostic CTA 
results were considered false positive if coronary 
angiography was negative and false negative if 
coronary angiography was positive, we also calculated 
NPVs and PPVs depending on pretest probabilities in a 
model excluding non-diagnostic CTA.
Based on the generalised linear mixed model with 
the test result as a dependent variable, we estimated 
mean logit sensitivity and specificity, between-study 
variability in logit sensitivity and specificity, and the 
covariance between them and the effect of covariates. 
Areas under the receiver operating characteristic 
curves were constructed using the observed data 
and model based predictions. These also included 
random effects, which reflect variability between 
studies and unobserved influential variables. The 
clinical performance of CTA was compared including 
non-diagnostic CTA results between women and 
men, between four age groups, and between the 
four angina pectoris types. Furthermore, it was 
compared with quantitative coronary angiography 
as the reference standard and the presence of core 
laboratories in the case of multicentre studies, to 
determine if this affected the primary outcomes. The 
influence of these covariates was evaluated by the 
likelihood ratio test. We did not search for the most 
parsimonious statistical model because, for clinical 
reasons, the type of chest pain, for instance, is pivotal 
and should be included. To compare the area-under-
the-curve results for inclusion versus exclusion of 
non-diagnostic examinations, we applied DeLongs’ 
test.28 Performance of CTA using up to 64 or more 
than 64 detector rows was compared empirically. We 
investigated publication bias using the rank based 
method for the arcsine difference of study specific 
sensitivities and specificities.29
As recommended by the PRISMA statement, we 
compared aggregate data of studies for which IPD 
was provided with those aggregate data of studies 
for which IPD was not provided to identify or exclude 
differences between these data based on a bivariate 
generalised linear mixed model with IPD available as 
a covariate.30 We calculated the likelihood ratio test for 
the models with and without this covariate. This model 
was estimated for aggregate 2×2 tables using the model 
of Chu and Cole.31 In our analyses, non-diagnostic CTA 
results were treated using an intention-to-diagnose 
approach (see above) as suggested by Schuetz and 
colleagues.16 Estimation was done with Stata 14, using 
the packages GLLAMM and gllapred for the predictions 
and MIDAS for the 2×2 diagnostic meta-analysis. 
Further statistical analyses were conducted by SAS 
version 9.4 (SAS Institute, Cary, NC, USA) and R 3.4,32 
and packages lme4,33 meta,34 and pROC.35 Model 
based estimates of sensitivity and specificity were 
obtained by averaging over the random effects using 
the R package lsmeans.36
Patient and public involvement
We have insufficient evidence to comment on whether 
patients were actively involved in the design or 
management of the 76 studies included and for which 
IPD were provided. In this study, given the privacy 
concerns of IPD sharing, it was also not practical to 
involve patients in reviewing this data. The results of 
the study will be disseminated using press releases 
and the website of the study coordinator.
Results
Included studies and study participants
We identified 154 eligible published studies, for which 
we sought IPD by contacting authors (fig 1). Overall, 
we identified 76 studies (74 published, 2 unpublished) 
for which IPD were provided for a total of 7813 
participants. Of these 76 studies, 11 (including 2481 
patients) had to be excluded from this main COME-CCT 
analysis because no information on angina pectoris 
presentation was recorded, chest pain was unstable, or 
patients had coronary artery stents or bypasses. Finally, 
a total of 5332 patients from the remaining 65 studies 
(63 published and two unpublished; supplementary 
table 1 in web appendix 2) were included in the main 
collaborative analysis, including 554 patients with 
non-diagnostic CTA examinations (fig 1). Risk of bias 
was low for all items in most studies, and applicability 
concerns were not present in any of the included studies 
assessed by the QUADAS-2 tool (supplementary tables 
2-4 and supplementary figures 1-2 in web appendix 
2). In most of the 78 studies for which IPD were not 
provided (for a total of 6684 patients included), the 
corresponding authors did not respond (56/78, 72%) 
and aggregate data were available for 76 studies, or 
6077 patients (fig 1).
Patient characteristics
Patient characteristics of the 5332 patients from 64 
studies available for IPD analysis and their assignment 
to pretest probability categories are presented in table 
1. Patient characteristics for each dataset including 
chest pain symptoms and risk factor distribution are 
listed in supplementary table 5 in web appendix 2. 
Technical characteristics of imaging tests for each 
dataset are summarised in supplementary table 6 
in web appendix 2. Table 1 shows empirical results 
for true positives and negatives, false positives and 
negatives, as well as non-diagnostic CTA results for 
different categories of clinical pretest probability. Up 
to a pretest probability of 40%, pretest probability 
predictions overestimated true CAD prevalence 
by about 10 percentage points using the updated 
version of the Diamond and Forrester method. Above 
a pretest probability of 50%, true CAD prevalence 
was underestimated by about 10 percentage points. 
Above a pretest probability of about 70%, empirical 
diagnostic accuracy including specificity decreased 
(table 1). Also, CTA using up to 64 versus more than 
64 detector rows led to significantly lower empirical 
sensitivity (86.5% v 93.4%, P=0.002) and specificity 
(72.6% v 84.4%, P<0.001, table 1). Non-diagnostic 
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examinations were rare for scanners with more than 
64 detector rows (2.9%), but considerably more 
frequent on those with up to 64 detector rows (11.5%, 
table 1).
Diagnostic performance of CTA depending on 
pretest probability
Figure 2 shows the relation between PPVs and NPVs of 
CTA and clinical pretest probability in the generalised 
linear mixed model including non-diagnostic 
examinations. Based on the statistical model, we 
found that for a pretest probability range of 7-67%, the 
treat threshold of more than 50% post-test probability 
(ischaemia testing recommended) and the no-treat 
threshold of less than 15% (consider other reasons for 
the chest pain) were obtained using CTA. At a pretest 
probability of 7%, the PPV of CTA was 50.9% (43.3% 
to 57.7%) and NPV was 97.8% (96.4% to 98.7%). At a 
pretest probability of 67%, the PPV was 82.7% (78.3% 
to 86.2%) and NPV was 85.0% (80.2% to 88.9%).
Additional studies identified
through contact with authors
Studies excluded
Titles or abstracts did not match
No original research articles
No patient level data available
No 50% cutoff value for CAD detection
Retrospective patient enrolment
CT + ICA not in all patients
CT scanners <12 slices
ICA not reference standard
Not published in English or German
Overlap with other studies
Not performed in native vessels
Including patients with atrial fibrillation
9019
117
75
52
39
28
26
25
25
21
14
4
Studies screened for eligibility aer duplicates removed
Studies identified through
database searching
12 712
Eligible studies, IPD sought for all
Studies for which IPD were not provided
(6684 participants)
78
Studies for which IPD were provided
(7813 participants)
76
12
9598
9445
Participants excluded*
No angina classification or missing
  data for PTP calculation
With stents or bypasses
Unstable angina
No CT or ICA data
Non-diagnostic ICA
1610
513
343
37
10
2481
Authors did not respond
Mail addresses did not work
Reasons for not participating
  No access to original data
  No possibility to participate
  Response aer deadline
  No willingness to participate
  Health issues
  Changed research focus
  Insufficient data
  No eligibility stated
  Technical issues
  Time constraints
56
3
19
154
7
2
2
2
1
1
1
1
1
1
Studies for which aggregate data were available
(6077 participants)
76
Aggregate data
(6077 participants)
76
IPD for this analysis
(5332 participants)
65
* Multiple reasons per participant possible
Fig 1 | PRISMA individual patient data (IPD) flow diagram. A total of 9598 studies were scanned after removing 
duplicates. After full text review of 580 publications, 154 studies remained for which IPD were sought. IPD were 
retrieved for 76 studies including 7813 participants. For this analysis, 2481 participants of 11 studies had to be 
excluded, mainly because angina pectoris type was not classified or other data for pretest probability (PTP) calculation 
were missing (1610). Further reasons for exclusion of participants from the main analysis included coronary stents or 
bypass grafts, unstable angina pectoris, and non-diagnostic, invasive, coronary angiography examinations. A total of 
5332 patients were included in this IPD analysis. ICA=invasive coronary angiography
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Table 1 | Baseline patient characteristics and empirical diagnostic performance of computed tomography angiography to diagnose coronary artery 
disease, stratified by pretest probability category and scanner detector rows
Overall 
(n=5332)
Pretest probability categories
0 to <10% 
(n=86)
10 to <20% 
(n=530)
20 to <30% 
(n=601)
30 to <40% 
(n=727)
40 to <50% 
(n=745)
50 to <60% 
(n=752)
60 to <70% 
(n=590)
70 to <80% 
(n=535)
80 to <90% 
(n=698)
90 to 100% 
(n=68)
Demographic characteristics (median (range) or No (%))
Median age 
(years) 61 (18-96) 47 (18-50) 56 (23-70) 59 (24-82) 57 (37-89) 55 (27-87) 63 (30-91) 70 (36-88) 55 (47-92) 66 (59-77) 80 (78-89)
Men 3473 (65) 0 29 (5) 211 (35) 509 (70) 576 (77) 507 (67) 391 (66) 484 (90) 698 (100) 68 (100)
Women 1859 (35) 86 (100) 501 (95) 390 (65) 218 (30) 169 (23) 245 (33) 199 (34) 51 (10) 0 0
Median body 
mass index
26.3  
(14.3-57.1)
25.6  
(17.9-39.3)
26.2  
(14.3-47.3)
25.9  
(16.1-44.8)
26.2  
(16.9-41.8)
26.4  
(17.5-45.2)
26.5  
(17.2-57.1)
26.4  
(15.5-56.2)
27.0  
(17.5-42.5)
26.9  
(16.9-56.7)
25.9  
(16.8-35.2)
Clinical presentation (No)
Typical angina 1967 0 0 4 43 137 247 306 464 698 68
Atypical angina 1592 1 138 269 235 280 339 260 70 0 0
Non-anginal  
chest pain 796 38 162 157 188 158 80 12 1 0 0
Other chest 
discomfort 977 47 230 171 261 170 86 12 0 0 0
Diagnostic performance (No or %)
CAD  
prevalence (%)* 48.3 17.4 24.0 32.1 40.9 46.8 46.8 53.7 68.6 71.6 82.4
TP 2251 14 120 176 272 321 310 256 317 420 45
TN 2031 52 313 312 334 287 294 194 103 134 8
FP 728 19 90 96 96 109 106 79 65 64 4
FN 322 1 7 17 25 28 42 61 50 80 11
NDX† 554 13 58 50 54 67 76 79 60 85 12
NDX rate (%)† 10.4 15.1 10.9 8.3 7.4 9.0 10.1 13.4 11.2 12.2 17.6
PPV (%) 75.6 42.4 57.1 64.7 73.9 74.7 74.5 76.4 83.0 86.8 91.8
NPV (%) 86.3 98.1 97.8 94.8 93.0 91.1 87.5 76.1 67.3 62.6 42.1
Sensitivity (%) 87.5 93.3 94.5 91.2 91.6 92.0 88.1 80.8 86.4 84.0 80.4
Specificity (%) 73.6 73.2 77.7 76.5 77.7 72.5 73.5 71.1 61.3 67.7 66.7
Diagnostic  
accuracy (%) 80.3 76.7 81.7 81.2 83.4 81.6 80.3 76.3 78.5 79.4 77.9
LR+ 3.32 3.49 4.23 3.88 4.10 3.34 3.32 2.79 2.23 2.60 2.41
LR− 0.17 0.09 0.07 0.12 0.11 0.11 0.16 0.27 0.22 0.24 0.29
CT scanners with ≤64 detector rows (No or %)
No of patients 4666 80 452 529 651 634 637 530 472 619 62
CAD  
prevalence (%) 48.2 17.5 24.1 31.2 41.8 45.5 46.0 54.0 67.4 72.5 85.5
TP 1943 13 102 150 248 264 256 226 270 372 42
TN 1757 47 265 273 295 247 246 170 95 114 5
FP 662 19 78 91 84 99 98 74 59 56 4
FN 304 1 7 15 24 24 37 60 48 77 11
NDX† 538 13 54 50 50 65 75 77 58 84 12
NDX rate (%)† 11.5 16.3 11.9 9.5 7.7 10.3 11.8 14.5 12.3 13.6 19.4
PPV (%) 74.6 40.6 56.7 62.2 74.7 72.7 72.3 75.3 82.1 86.9 91.3
NPV (%) 85.2 97.9 97.4 94.8 92.5 91.1 86.9 79.9 66.4 59.7 31.3
Sensitivity (%) 86.5 92.9 93.6 90.9 91.2 91.7 87.4 79.0 84.9 82.9 79.2
Specificity (%) 72.6 71.2 77.3 75.0 77.8 71.4 71.5 69.7 61.7 67.1 55.6
Diagnostic  
accuracy (%) 79.3 75.0 81.2 80.0 83.4 80.6 78.8 74.7 77.3 78.5 75.8
LR+ 3.16 3.23 4.12 3.64 4.11 3.20 3.07 2.61 2.22 2.52 1.78
LR− 0.19 0.10 0.08 0.12 0.11 0.12 0.18 0.30 0.24 0.26 0.37
CT scanners with >64 detector rows (No or %)
No of patients 558 6 73 62 66 87 103 55 41 59 6
CAD prevalence 
(%)* 46.1 16.7 21.9 37.1 30.3 54.0 49.5 50.9 75.6 62.7 50.0
TP 240 1 16 21 19 44 46 27 29 34 3
TN 254 5 46 36 39 33 47 22 6 17 3
FP 47 0 11 3 7 7 5 5 4 5 0
FN 17 0 0 2 1 3 5 1 2 3 0
NDX† 16 0 4 0 4 2 1 2 2 1 0
NDX rate (%)† 2.9 0.0 5.5 0.0 6.1 2.3 1.0 3.6 4.9 1.7 0.0
PPV (%) 83.6 100 59.3 87.5 73.1 86.3 90.2 84.4 87.9 87.2 100
NPV (%) 93.7 100 100 94.7 97.5 91.7 90.4 95.7 75.0 85.0 100
Sensitivity (%) 93.4 100 100 91.3 95.0 93.6 90.2 96.4 93.5 91.9 100
Specificity (%) 84.4 100 80.7 92.3 84.8 82.5 90.4 81.5 60.0 77.3 100
Diagnostic  
accuracy (%) 88.5 100 84.9 91.9 87.9 88.5 90.3 89.1 85.4 86.4 100
LR+ 5.98 ∞ 5.18 11.87 6.24 5.35 9.38 5.21 2.34 4.04 ∞
LR− 0.08 0 0 0.09 0.06 0.08 0.11 0.04 0.11 0.10 0
TP=true positives; TN=true negatives; FP=false positives; FN=false negatives; PPV=positive predictive value; NPV=negative predictive value; LR+=positive likelihood ratio; LR−=negative likelihood 
ratio; NDX=non-diagnostic results.
The empirical results were derived from raw data and thus differ from the results of the statistical model.
*CAD prevalence was defined by coronary angiography.
†Non-diagnostic results were included in the estimation of diagnostic accuracy as false positives if the reference standard was negative, and as false negative if the reference standard was positive.
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When excluding non-diagnostic examinations, the 
PPV at a pretest probability of 7% was 68.0% (60.5% 
to 74.6%) and NPV was 98.3% (97.0% to 99.1%; 
table 2); at a pretest probability of 67%, the PPV was 
88.9% (85.3% to 91.7%) and NPV was 91.4% (87.8% 
to 94.2%). The relation between PPVs and NPVs of 
CTA and clinical pretest probability in the generalised 
linear mixed model after excluding non-diagnostic 
CTA examinations is shown in supplementary figure 3 
in web appendix 2. The model based predictive values 
for 7% and 67% pretest probabilities as well as for 
15% and 50% pretest probabilities as recommended 
by the European Society of Cardiology guidelines are 
listed in table 2 for both, including and excluding non-
diagnostic CTA results.
Clinically important subgroups
The sensitivity of CTA for all patients was 95.2% 
(92.6% to 96.9%) and the specificity was 79.2% 
(74.9% to 82.9%, table 3). The sensitivity of CTA for 
women and men was 93.5% (89.6% to 96.0%) and 
95.8% (93.4% to 97.4%), respectively, while the 
specificity was 80.6% (75.9% to 84.6%) and 77.4% 
(72.4% to 81.8%, likelihood ratio test11.28, df: 2, 
P<0.001, table 3). Empirical data of women and men 
and their assignment to pretest probability categories 
are tabulated in supplementary tables 7 and 8 in web 
appendix 2. For patients older than 75, the sensitivity 
of CTA was 93.2% (88.6% to 96.0%) and the specificity 
was 73.6% (65.7% to 80.2%, table 3).
In the receiver operating characteristic analysis, CTA 
including non-diagnostic results had an area under the 
curve of 0.897 (95% confidence interval 0.889 to 0.906) 
versus a significantly larger area under the curve when 
non-diagnostic results were excluded (0.949 (0.943 to 
0.954), P<0.001, fig 3). All further results are provided 
for the analyses with inclusion of non-diagnostic CTA 
examinations. The diagnostic performance of CTA was 
lower in women than in men (area under the curve 
0.874 (0.858 to 0.890) v 0.907 (0.897 to 0.916), 
P<0.001, fig 3). A descriptive analysis revealed that 
the heart rate during CTA was higher in women than in 
men (supplementary figure 4 in web appendix 2). Heart 
rate was the only factor significantly associated with 
a non-diagnostic CTA examination (supplementary 
table 9 in web appendix 2). The lowest diagnostic 
performance of CTA was found in patients older than 
75 (0.864, 0.834 to 0.894, P=0.018 v all other age 
groups, fig 3). Empirical data of patients of different 
age groups and their assignment to pretest probability 
categories are listed in supplementary tables 10-13 
in web appendix 2. In a descriptive analysis, patients 
older than 75 had significantly higher coronary artery 
calcium scores than younger patients (supplementary 
figure 5 in web appendix 2).37 Accuracy of CTA was not 
significantly influenced by the angina pectoris type 
(area under the curve for typical angina 0.895 (0.873 
to 0.917) v atypical angina 0.898 (0.884 to 0.913) v 
non-anginal chest pain 0.884 (0.870 to 0.899) v other 
chest discomfort: 0.915 (0.897 to 0.934), fig 3).
Further post hoc analyses
Empirical data of patients with different chest pain 
types and their assignment to pretest probability 
categories are tabulated in supplementary tables 
14-17 in web appendix 2. The receiver operating 
characteristic analysis after excluding non-diagnostic 
CTA results showed that accuracy was significantly 
reduced only in patients older than 75, whereas sex 
was no longer a significant factor (supplementary 
figure 6 in web appendix 2). Overall, 3615 (69%) 
Table 2 | Model based predictive values of computed tomography angiography for obstructive coronary artery disease, 
including and excluding non-diagnostic results
Pretest probability of coronary artery disease (%)
7 15 50 67
Including non-diagnostic examinations
PPV (%; 95% CI) 50.9 (43.3 to 57.7) 55.8 (48.6 to 62.3) 75.4 (70.5 to 79.5) 82.7 (78.3 to 86.2)
NPV (%; 95% CI) 97.8 (96.4 to 98.7) 97.1 (95.4 to 98.2) 90.9 (87.5 to 93.4) 85.0 (80.2 to 88.9)
Excluding non-diagnostic examinations
PPV (%; 95% CI) 68.0 (60.5 to 74.6) 71.6 (64.7 to 77.5) 84.5 (80.0 to 87.9) 88.9 (85.3 to 91.7)
NPV (%; 95% CI) 98.3 (97.0 to 99.1) 97.9 (96.4 to 98.8) 94.4 (92.0 to 96.3) 91.4 (87.8 to 94.2)
PPV=positive predictive value, NPV=negative predictive value.
Pretest probability (%)
P
os
t-
te
st
 p
ro
ba
bi
lit
y 
(%
)
0 20 40 60 80 100
0
20
40
60
80
100
Positive PV
1-Negative PV
Fig 2 | Clinical diagnostic performance of computed tomography angiography to 
diagnose obstructive coronary artery disease as a function of pretest probability. The 
x axis represents the predicted clinical pretest probability, and the y axis shows the 
post-test probabilities and thus the positive predictive value (PV) and 1−negative PV 
with their 95% confidence intervals, based on the generalised linear mixed model 
including non-diagnostic CTA examinations. Results for the generalised linear mixed 
model excluding non-diagnostic CTA examinations are shown in supplementary figure 3 
in web appendix 2. Disease probabilities were predicted by averaging over the random 
effects distribution. AUC=area under the curve
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of 5266 patients were analysed with quantitative 
coronary angiography as the reference standard. We 
found no significant difference in diagnostic accuracy 
of CTA, irrespective of whether quantitative coronary 
angiography was used or not, while the use of core 
laboratories was associated with lower sensitivity and 
specificity (supplementary table 18).
Participation and publication bias
The comparison of the diagnostic accuracy studies for 
which IPD were provided with those studies for which 
only aggregate data were available (fig 1) showed 
no significant difference in diagnostic performance 
(P=0.73, fig 4 and table 4). We found no publication 
bias (supplementary figure 7 in web appendix 2), 
and heterogeneity analysis yielded variances of 
random effects of 0.673 for 1−specificity and 3.667 
for sensitivity (table 5). We obtained similar values 
after adjusting age, sex, and type of chest pain (table 
6), indicating that these covariates do not explain 
heterogeneity between studies. Table 6 also presents 
the model coefficients used for generating the receiver 
operating characteristic curves.
Discussion
In this pooled analysis of patient level data, we show 
that coronary CTA is most appropriately implemented 
for clinical decision making in patients with suspected 
obstructive CAD and a pretest probability ranging 
from 7% to 67%. In this low-to-intermediate clinical 
probability range, coronary CTA was able to accurately 
stratify patients into those with a disease post-test 
probability of below 15%, in whom other reasons for 
the chest pain should be considered, and those with 
a probability above 50%, in whom further testing is 
recommended.3
Our study also showed that the diagnostic 
performance of CTA was not significantly influenced 
by the angina pectoris type, but it was higher in 
men and lower in older patients. After we excluded 
non-diagnostic examinations from the analysis, 
the accuracy of CTA improved and the difference in 
diagnostic performance between female and male 
patients became non-significant. Moreover, diagnostic 
examinations are now more commonly conducted by 
computed tomography scanners with more than 64 
detector rows, which had lower rates of non-diagnostic 
examinations.
Clinical context and guidelines
Current European and US guidelines recommend 
calculating patients’ pretest probability of CAD to 
guide diagnostic decisions.3 38 The European Society 
of Cardiology specifically recommends considering 
CTA in patients with 15-50% pretest probability 
of obstructive CAD,3 whereas the NICE guideline 
recommends coronary CTA as the primary imaging test 
for all patients with possible angina and suspected 
obstructive CAD.4 Our results show that using the 
no-treat/treat threshold approach, CTA offers good 
to excellent results in pretest probability range of 7% 
to 67%. The procedure yields a post-test probability 
below 15%, where other reasons for the chest pain 
should be considered, in case of negative CTA (that 
is, NPV ≥85%); and above 50%, where ischaemia 
testing is recommended, in case of positive CTA (that 
is, PPV ≥50%). Since no IPD meta-analysis has so far 
investigated in which patients CTA has the highest 
diagnostic performance, the results presented here 
might have important implications for current 
guidelines. The results of the diagnostic performance 
model can also be used to define the appropriate 
pretest probability range depending on the NPV and 
PPV deemed to be acceptable for the specific diagnostic 
purpose.
The main clinical strength of coronary CTA is its high 
NPV, and this is supported by our findings, which show 
that CTA can also detect both obstructive and non-
obstructive CAD and therefore is a suitable imaging 
modality to guide subsequent management.39 This 
may make patient management more efficient and can 
also lower costs, not least by reducing the high rate of 
negative coronary angiographies performed annually. 
Recently published randomised clinical trials support 
these assumptions. Although the PROMISE trial—
which compared CTA with an initial functional testing 
strategy in the evaluation of chest pain—did not 
show a reduction in major adverse cardiovascular 
events (defined as death, myocardial infarction, and 
unstable angina needing hospital admissions, or a 
major procedural complication), subsequent invasive 
coronary angiography was more effective in the CTA 
group.40
The SCOT-HEART trial prospectively compared 
standard care with standard care plus CTA for the 
diagnosis of CAD in patients with recent onset 
chest pain.41 In the trial, CTA was found to increase 
diagnostic certainty, increase the identification of 
obstructive and non-obstructive CAD, and eliminate 
the need for further downstream stress imaging 
tests.41 Furthermore, the five year clinical outcome 
analysis of SCOT-HEART showed that standard care 
plus CTA resulted in a halving of fatal and non-fatal 
myocardial infarction without increasing the five year 
rate of coronary revascularisations but initiating more 
targeted preventive and anti-anginal treatments.9 
However, some controversy remains about the use of 
Table 3 | Model based sensitivity and specificity of computed tomography angiography 
for obstructive coronary artery disease, according to total population and subgroups
Diagnostic performance estimate
Sensitivity Specificity
Estimate (SE) 95% CI Estimate (SE) 95% CI
Total 95.2 (1.1) 92.6 to 96.9 79.2 (2.1) 74.9 to 82.9
Sex
 Women 93.5 (1.6) 89.6 to 96.0 80.6 (2.2) 75.9 to 84.6
 Men 95.8 (1.0) 93.4 to 97.4 77.4 (2.4) 72.4 to 81.8
Age
 >75 93.2 (1.8) 88.6 to 96.0 73.6 (3.7) 65.7 to 80.2
 >65 to ≤75 95.0 (1.2) 92.0 to 96.9 77.3 (2.6) 71.8 to 82.0
 >50 to ≤65 95.1 (1.2) 92.3 to 97.0 80.6 (2.1) 76.1 to 84.5
 ≤50 95.5 (1.4) 91.8 to 97.6 83.8 (2.4) 78.6 to 87.9
SE=standard error.
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coronary CTA as the first line diagnostic test in patients 
with stable chest pain and suspected CAD,42 and our 
IPD meta-analysis provides insights about in which 
patients CTA has highest predictive values.
Our IPD meta-analysis data can thus help 
physicians in better identifying the patients for 
whom coronary CTA is the most appropriate 
diagnostic test. Whether CTA can further improve 
clinical effectiveness in patients with a clinical 
indication for coronary angiography is an 
important question. The CAD-Man study showed 
that coronary CTA can reduce the need for invasive 
coronary angiography by up to 80% and can reduce 
procedural complications.8 A similar safety profile 
with non-inferiority of CTA versus invasive coronary 
angiography in terms of major cardiovascular events 
at one year was found in the CONSERVE trial.43 
However, coronary CTA still has to be analysed 
in a multicentre study of patients with a clinical 
indication for invasive coronary angiography, and 
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Excluding NDX 0.95 (0.94 to 0.96)
All patients 0.90 (0.89 to 0.91) P<0.001
Male 0.91 (0.90 to 0.92) P<0.001
Female 0.87 (0.86 to 0.89)
>75 years 0.86 (0.83 to 0.89)
P = 0.018 (v all other age groups)
>65 to ≤75 years 0.90 (0.88 to 0.91)
>50 to ≤65 years 0.90 (0.89 to 0.92)
≤50 years 0.90 (0.88 to 0.93) Other chest discomfort 0.92 (0.90 to 0.93)
Typical angina 0.90 (0.87 to 0.92)
Atypical angina 0.90 (0.88 to 0.91)
Non-anginal chest pain 0.88 (0.87 to 0.90)
Fig 3 | Receiver operating characteristic curves of computed tomography angiography for obstructive coronary artery disease, by subgroup and after 
excluding non-diagnostic examinations (NDX). Diagnostic performance results are shown for all patients versus results obtained after exclusion 
of non-diagnostic test results. The inclusion of all patients (top left panel) resulted in lower performance, which is a more accurate prediction 
of the real world performance to be expected. Thus, all subgroup comparisons in the other three panels are provided for all patients (including 
non-diagnostic examinations): diagnostic performance was higher in men and lower in patients older than 75, and angina pectoris types were not 
significantly associated with performance. Curves were generated by a generalised linear mixed model and predictions based on these models. 
Computations were performed with the statistical package R and packages lme4 and pROC. Areas under the curve were constructed by use of 
the observed data and model based predictions, which also included the random effects reflecting variability between studies and unobserved 
influential variables
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the randomised DISCHARGE trial will provide more 
data in this regard.44
Comparison with other studies
Meta-analyses using aggregated data from studies 
that mostly excluded patients with non-diagnostic 
CTA examinations or considered them positive have 
reported a mean sensitivity for CTA per patient of 
97.2% to 100% and a specificity of 87.4% to 89%.21 45 
We found lower sensitivities and specificities when 
including non-diagnostic tests as false positives or 
negatives in our IPD analysis in a worst case scenario, 
confirming that the performance of diagnostic tests is 
lower when non-diagnostic test results are considered 
and not merely excluded from the analysis.16 Our 
data also confirm the findings of a study level meta-
regression analysis suggesting a hyperbolic decrease 
and increase of the NPVs and PPVs with increasing 
pretest probability, respectively.7 We also showed that 
pretest probability overestimated true CAD prevalence 
by about 10 percentage points up to a pretest probability 
of 40%; while above a pretest probability of 50%, 
true CAD prevalence was underestimated by about 
10 percentage points. Future trials should address 
how to improve the accuracy of pretest probability 
estimation in patients with suspected CAD. Also, CTA 
using more than 64 detector rows led to significantly 
higher empirical sensitivity and specificity, indicating 
that recent CTA technology with more than 64 rows 
should be used.
Criteria have been proposed to ensure a reasonable 
use of coronary CTA.46 47 Our study can help refine 
these criteria by allowing to individually define the 
appropriateness of coronary CTA based on the patient’s 
clinical pretest probability. Moreover, according to our 
findings, one should be cautious to use CTA in patients 
with a clinical pretest probability exceeding 67% since 
the NPV drops below 85%. In addition, the odds to find 
obstructive CAD on CTA (and thus also the likelihood 
to require another invasive test after non-invasive CTA) 
increases with the pretest probability. On the other 
hand, the PPV of coronary CTA becomes rather low in 
patients with a pretest probability of less than 7%, so 
that, in this situation, about half of the positive CTA 
examinations would result in unnecessary further 
testing. For ease of understanding, we visualised 
the predictive values of coronary CTA depending on 
pretest probability in figure 2. The European Society 
of Cardiology guidelines suggest a pretest probability 
range of 15-50% for diagnostic testing with coronary 
CTA. In this narrower range of pretest probability, CTA 
had an NPV and PPV of at least 90.9% and 55.8%, 
respectively.
From a clinical perspective, the diagnostic per-
formance of CTA was not influenced by the angina 
pectoris type and was equally effective in ruling out 
angiographic CAD in patients with different angina 
pectoris types. Even though the reductions in diagnostic 
performance of CTA were small, decision makers 
should be aware that CTA has a slightly lower accuracy 
in patients older than 75, and in women compared 
with men, if non-diagnostic CTA results are included 
in the analysis. As mentioned above, non-diagnostic 
examinations are rarely seen when using computed 
tomography scanners with more than 64 detector rows; 
and when excluding non-diagnostic examinations, 
performance of CTA was similar in women and men. 
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Fig 4 | Summary receiver operating characteristic (SROC) curves for studies using 
computed tomography angiography to diagnose obstructive coronary artery disease, 
with and without individual participant data (IPD) available. Curves are shown for 
studies with IPD available versus studies for which no IPD were available. Curves 
were calculated by aggregated data methodology (SROC curves) both for panels and 
after excluding non-diagnostic test results, which were not consistently available 
in publications of studies that did not provide IPD. Of 76 studies that provided IPD, 
aggregate data were not available for seven studies (two unpublished), leaving 69 
for the analysis of studies with IPD; of 78 studies that did not provide IPD, 76 had 
aggregate data available (fig 1); there was no significant difference in diagnostic 
performance between these two groups of diagnostic accuracy studies (P=0.73). 
Further details shown in table 4. For study number details, see supplementary figure 8. 
AUC=area under the curve
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Similarly, our results showed that women had higher 
heart rates than men when examined by CTA and 
higher rates were the only factor associated with non-
diagnostic examinations. Similar diagnostic accuracy 
of coronary CTA in men and women was reported by 
a multicentre study including 291 patients48 and by 
two single centre studies including 570 and 1372 
patients.49 50 In our IPD analysis of 3473 men and 
1859 women including non-diagnostic examinations, 
we showed a small reduction in the area under the 
curve of CTA in women by 0.023 compared with men 
(fig 3). This difference might be explained by women 
being more likely to have high heart rates during CTA, 
which was the only factor significantly associated with 
non-diagnostic CTA results.
Strength and limitations of study
Our study had strengths and limitations. IPD meta-
analyses are considered the gold standard of systematic 
reviews. Even though the individual diagnostic 
accuracy studies were similar in terms of inclusion 
criteria and reference standard definitions, they varied 
in geographical origin and composition. Although this 
study was done in 22 countries and has a multicentric 
and multicontinental design, participation was not 
equally distributed across the globe, and ethnicity was 
not collected in data analysis. Moreover, obstructive 
CAD was defined by invasive coronary angiography 
as angiographically significant CAD in all patients, 
quantitative analysis of invasive angiography was used 
in 69% of patients, and functional definitions of CAD 
(eg, including invasive fractional flow reserve) were 
not used in the original studies. Thus, findings might 
not be generalisable to real world practice, although 
additional invasive fractional flow reserve is used in 
less than 10% of examinations worldwide,51 making 
the findings relevant for current clinical practice.
To define no-treat and treat thresholds, we estimated 
pretest probabilities by using the updated Diamond 
and Forester model (also recommended by the current 
the European Society of Cardiology guidelines). This 
calculator is validated for patients with suspected 
CAD referred for invasive coronary angiography, which 
is also the setting of this analysis. Other prediction 
models for pretest probabilities do not focus on this 
cohort but on patients referred for non-invasive 
assessment, as in the CONFIRM study.52 Furthermore, 
although results of exercise tests can also be included 
in pretest calculation, they are not included in currently 
validated probability calculators and could thus not be 
considered in our review.53
As shown in table 1, the most frequently used 
computed tomography scanners had 64 detector rows 
(2438 of 5332 patients); thus, CTA performance in 
clinical practice using state-of-the-art technology with 
more than 64 detector rows could have been even 
better. An important limitation of our IPD analysis of 
the clinical performance of coronary CTA was that not 
all 154 studies that were identified through our search 
strategy could be included because the responsible 
corresponding authors did not provide IPD. However, 
we sought to systematically retrieve all IPD from the 
studies identified by the systematic review and, despite 
several reminders, a relevant proportion of authors did 
not reply at all (56/154, 36%) or indicated that they 
could not participate in the COME-CCT Consortium 
because they had no access to original data (7/154, 
5%). According to a systematic review of data retrieval 
in IPD meta-analyses, 68% of meta-analyses retrieved 
IPD from at least 80% of a median of only 14 eligible 
studies.54 With 154 eligible studies, our study was 
relevantly larger, which has been shown to complicate 
retrieval.54
Diagnostic performance results were similar in studies 
for which IPD were available versus those for which 
no IPD were provided. To include unpublished grey 
literature, we systematically asked all corresponding 
authors of the identified published studies about 
further unpublished analyses and systematically 
searched clinicaltrials.gov for unpublished diagnostic 
accuracy studies of coronary CTA and invasive 
coronary angiography registered in this database. With 
this approach, we found two unpublished studies that 
could be included in the COME-CCT database. Our 
findings did not show evidence of publication bias, 
but we found heterogeneity between studies, pointing 
to potentially unknown site specific factors that might 
have influenced diagnostic accuracy. All studies 
included patients who had suspected CAD and were 
clinically indicated to undergo coronary angiography. 
This gave us the opportunity to compare results 
from research CTA with clinically indicated coronary 
angiography in all patients to avoid verification bias. 
But the results are representative for patients clinically 
Table 5 | Heterogeneity analysis of diagnostic accuracy studies using computed 
tomography angiography to diagnose obstructive coronary artery disease: overall 
statistical model without covariates
Generalised linear mixed model fit by maximum likelihood
Fixed effects*
Intercept Estimate (SE), −1.336 (0.125); z=−10.72; P<0.001
CAD present Estimate (SE), 4.313 (0.294); z=14.69; P<0.001
Random effects†
Study No (intercept) Variance, 0.673; SD, 0.8203
CAD present Variance, 3.667; SD, 1.9149; correlation, −0.75
SE=standard error; SD=standard deviation; CAD=coronary artery disease. 
*Data for fixed effects are estimates (standard error) of regression coefficients, z value, and P value. The intercept 
is 1−specificity, and the sum of the intercept and CAD represents sensitivity.
†Data are for random effects are variance, standard deviation, and correlation. Random effects quantify the 
variability between studies. The variance of the random effects of the intercept corresponds to the between 
study variability of 1−specificity, and the random effects variance of CAD denotes the between study variability 
of sensitivity.
Table 4 | Study specific diagnostic accuracy of computed tomography angiography 
for coronary artery disease, comparing aggregated data from studies with individual 
participant data (IPD) versus aggregated data from studies without IPD
Estimate (95% CI)
Sensitivity Specificity
All studies 0.97 (0.97 to 0.98) 0.87 (0.85 to 0.88)
Studies with IPD* 0.97 (0.96 to 0.98) 0.86 (0.83 to 0.88)
Studies without IPD* 0.98 (0.97 to 0.98) 0.87 (0.84 to 0.90)
Heterogeneity analysis, IPD=1 Likelihood ratio test, χ2=0.62 P=0.73
*Studies with IPD=studies for which IPD were provided; studies without IPD=studies for which IPD were not 
provided. There was no relevant difference between these two groups of studies.
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referred for coronary angiography, and there was 
likely to be bias particularly at the extremes of pretest 
probability. For instance, individuals with low pretest 
probability were likely to have other unmeasured risk 
factors that increased their clinical probability, which 
could have overestimated PPVs of CTA.
Conclusions
In a no-treat/treat threshold model, the diagnosis 
of obstructive CAD using coronary CTA in patients 
with stable chest pain was most accurate when the 
clinical pretest probability was between 7% and 67%. 
Performance of CTA was not influenced by the angina 
pectoris type, was slightly higher in men, and was 
lower in older patients.
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